ACADIA PHARMACEUTICALS INC. Repayments of Long-Term Debt
ACADIA PHARMACEUTICALS INC. (ACAD) reported Repayments of Long-Term Debt of $9.00 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2012-05-08
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for the quarter ending 2012-03-31 was $9.00K, a 79.07% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for the quarter ending 2011-12-31 was $9.00K, a 78.57% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for the quarter ending 2011-09-30 was $12.00K, a 80.00% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for the quarter ending 2011-06-30 was $14.00K.
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for fiscal 2011 was $78.00K, a 77.90% decline from fiscal 2010.
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for fiscal 2010 was $353.00K, a 53.67% decline from fiscal 2009.
- ACADIA PHARMACEUTICALS INC. repayments of long-term debt for fiscal 2009 was $762.00K.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2012-03-31 | $9.00K 10-Q · filed 2012-05-08 | $18.00K derived: sum of 2 quarters · filed 2012-05-08 | $30.00K derived: sum of 3 quarters · filed 2012-05-08 | $44.00K derived: sum of 4 quarters · filed 2012-05-08 |
| 2011-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $21.00K derived: sum of 2 quarters · filed 2012-03-06 | $35.00K derived: sum of 3 quarters · filed 2012-03-06 | $78.00K 10-K · filed 2012-03-06 |
| 2011-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $26.00K derived: sum of 2 quarters · filed 2011-11-09 | $69.00K 10-Q · filed 2011-11-09 | $111.00K derived: sum of 4 quarters · filed 2012-05-08 |
| 2011-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-10 | $57.00K 10-Q · filed 2011-08-10 | $99.00K derived: sum of 3 quarters · filed 2012-05-08 | $159.00K derived: sum of 4 quarters · filed 2012-05-08 |
| 2011-03-31 | $43.00K 10-Q · filed 2012-05-08 | $85.00K derived: sum of 2 quarters · filed 2012-05-08 | $145.00K derived: sum of 3 quarters · filed 2012-05-08 | |
| 2010-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $102.00K derived: sum of 2 quarters · filed 2012-03-06 | $353.00K 10-K · filed 2012-03-06 | |
| 2010-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $311.00K 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $251.00K 10-Q · filed 2011-08-10 | |||
| 2009-12-31 | $762.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |